Appln. No. 10/721,742 Amd. dated June 27, 2006 Reply to Office Action of May 17, 2006

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

## Listing of Claims:

Claims 1-5 (Cancelled).

method for treating or inhibiting the development of brain inflammation due to the trauma to the brain resulting from surgery, comprising administering to a mammal in need thereof a therapeutically effective amount of pranlukast or a pharmaceutically acceptable salt thereof, which does not cross or minimally crosses the blood brain barrier to treat or inhibit the development of brain inflammation due to trauma to the brain resulting from surgery.

Claim 7 (Cancelled).

8 (Currently amended). The method of claim [[2]]  $\underline{6}$ , further comprising repeating the administering step until the white blood cell count reaches a normal level in cerebrospinal fluid.

9 (Currently amended). The method of claim [[1]]  $\underline{6}$ , wherein the administering step is performed pre-operatively before brain surgery or before an invasive brain operation.

Claim 10 (Cancelled).

Appln. No. 10/721,742 Amd. dated June 27, 2006 Reply to Office Action of May 17, 2006

11(Currently amended). The method of claim [[1]]  $\underline{6}$ , wherein the therapeutically effective amount of pranlukast is in a range of about 100 mg/day to 2000 mg/day.

12 (Currently amended). The method of claim [[1]]  $\underline{6}$ , wherein the therapeutically effective amount of pranlukast is in a range of about 200 mg/day to 1000 mg/day.

13 (Currently amended). The method of claim [[1]]  $\underline{6}$ , wherein the therapeutically effective amount of pranlukast is in a range of about 400 mg/day to 800 mg/day.

14 (Currently amended). The method of claim [[1]]  $\underline{6}$ , wherein the mammal is a human.

Claims 15-24 (Cancelled).